Psilocybin Fails to Deliver Lasting Behavioral Changes in Mouse Depression Models

The investigation administered psilocybin to mice in validated depression assays including forced swim and tail suspension tests. Acute reductions in immobility occurred within hours but returned to baseline by one month, contrasting with some prior reports of prolonged neuroplasticity markers. Researchers tracked serotonin receptor occupancy and BDNF levels yet observed no persistent circuit remodeling sufficient to alter behavior long-term.

This outcome aligns with broader patterns where rodent psychedelic responses often prove shorter-lived than human trial claims. Human studies frequently rely on small samples and subjective scales prone to expectancy bias, while mice allow direct measurement of locomotion and anhedonia without placebo confounds. Translation gaps between species remain substantial given differences in cortical complexity and dosing equivalents.

Optimistic narratives around rapid, durable psychedelic benefits for depression therefore require reevaluation. Regulatory bodies should prioritize large-scale, sham-controlled human RCTs with objective endpoints before expanding access. Next steps include testing repeated dosing regimens and alternative models such as chronic stress paradigms to determine if benefits can be stabilized.